Physician profile
Kenny C Nall
NPI 1710961727
$6,077.23
in general payments reported to CMS, 2019-2025
37 companies · $2,144 in 2025
The $2,144 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2021: $155 · 2022: $219 · 2023: $1,719 · 2024: $1,685 · 2025: $2,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,468 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,467.93 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,059.71 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,103.63 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.34 | 2019-2025 | Ofev, Jascayd |
| Regeneron Healthcare Solutions, INC. | $277.67 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $229.85 | 2019-2023 | Yupelri, Yupelri |
| Janssen Pharmaceuticals, INC | $178.21 | 2019-2021 | |
| Insmed, INC. | $174.09 | 2024-2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $131.41 | 2024-2025 | |
| Grifols USA, LLC | $127.41 | 2023-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $116.21 | 2025 | Ohtuvayre |
| Philips North America LLC | $109.44 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Merck Sharp & Dohme LLC | $98.30 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.00 | 2021-2023 | Lifevest |
| Baxter Healthcare | $90.34 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Resmed Corp | $76.35 | 2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenny Nall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.